Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19111


RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of celecoxib may prevent or treat head and neck cancer. PURPOSE: This randomized phase II trial is studying celecoxib to see how well it works compared to placebo in preventing head and neck cancer in patients with oral leukoplakia.

Study summary:

OBJECTIVES: Primary - Compare the clinical efficacy of celecoxib vs placebo, in terms of inducing regression of oral leukoplakia lesions, in patients with hyperplastic or dysplastic oral leukoplakia. Secondary - Determine the effect of this drug in modulating multiple intermediate biomarkers (e.g., COX-2, PPARγ, or PPARδ) in normal and hyperplastic or dysplastic oral epithelia of these patients. - Determine the safety of this drug in these patients. - Determine the cost-effectiveness of this drug as a chemopreventative agent in these patients. OUTLINE: This is a randomized, double-blind, placebo-controlled, cross-over study. Patients are stratified according to the pathology of the leukoplakia lesion (dysplasia vs hyperplasia). Patients are randomized to 1 of 2 arms. - Arm I: Patients receive oral celecoxib twice daily for 3 months. - Arm II: Patients receive oral placebo twice daily for 3 months. All patients undergo biopsy. Patients then cross-over to the opposite treatment arm for 3 months. In both arms, treatment continues in the absence of unacceptable toxicity or disease progression. Patients are followed at 1 month. PROJECTED ACCRUAL: A total of 27-60 patients (18-40 for study drug, 9-20 for placebo before cross-over) will be accrued for this study.


DISEASE CHARACTERISTICS: - Diagnosis of oral leukoplakia with hyperplasia or dysplasia - Documented by baseline biopsy of oral lesions suspicious for leukoplakia - For patients using dentures over the past 6 months, only lesions located on the ventral-lateral tongue or floor of the mouth are allowed - No leukoplakia/hyperplasia secondary to mechanical irritation - No carcinoma in situ of the oral cavity PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Not specified Life expectancy - At least 1 year Hematopoietic - Hemoglobin ≥ 10 g/dL (women) OR ≥ 11 g/dL (men) Hepatic - AST or ALT normal - Bilirubin normal Renal - Creatinine normal OR - Creatinine clearance ≥ 60 mL/min Cardiovascular - No myocardial infarction within the past 12 months - No known active ischemic cardiac disease by stress test or echocardiogram Gastrointestinal - No history of gastrointestinal hemorrhage - No known gastrointestinal ulcers within the past 2 years unless there is documentation of healed lesions by upper endoscopy - No active or suspected peptic ulcer disease - Negative stool guaiac test Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 2 months after study treatment - No use of snuff or chewing tobacco within the past 2 months - No active invasive malignancy within the past 3 years except nonmelanoma skin cancer or in situ carcinomas - No clinical evidence of chronic infectious disease - No clinical evidence of connective tissue disease - No known hypersensitivity (asthma, urticaria, or acute rhinitis induced by NSAIDs) to aspirin or other NSAIDs - No known hypersensitivity to sulfonamides PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - At least 6 months since prior chronic or frequent use of systemic glucocorticoids - No concurrent chronic or frequent use of systemic glucocorticoids Radiotherapy - Not specified Surgery - Not specified Other - No prior chronic or frequent (> 100 mg per day aspirin equivalent) use of nonsteroidal anti-inflammatory drugs (NSAIDs) for 7 of the past 14 days - At least 3 months since prior experimental therapy - No concurrent chronic or frequent use of NSAIDs - Cardioprotective doses of aspirin ≤ 100 mg daily are allowed

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

Official Title:

A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia

Overall Status:


Study Phase:

Phase 2



Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Fox Chase Cancer Center

Oversight Authority:

United States: Federal Government

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Masking: Double-Blind, P

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:

Overall Contact Information

Official Name:Paul F. Engstrom, MD
Principal Investigator
Fox Chase Cancer Center

Study Dates

Start Date:November 2003
Completion Date:January 2005
Completion Type:Actual
Primary Completion Date:January 2005
Primary Completion Type:Actual
Verification Date:July 2013
Last Changed Date:July 9, 2013
First Received Date:January 7, 2005

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Drug

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Fox Chase Cancer Center
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.